Metástasis | Jotup

NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors

Retrieved on:

Wednesday, August 4, 2021

Clinical medicine, Medicine, Health, Orphan drugs, Medical physics, Brain tumor, Oncology, Bevacizumab, Radiation therapy, Breast cancer, Metástasis, Cancer

The trial will investigate the "synergy" that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors.

Key Points:

The trial will investigate the "synergy" that FUS-mediated opening of the blood-brain barrier (BBB) has on improving the therapeutic effect of radiotherapy treatment in patients with end-stage primary brain tumors.
If this combined treatment can safely enhance the effect of radiotherapy, NaviFUS' believes this treatment can also be extended to metastatic brain tumors from lung cancer, breast cancer, etc.
At the same time, NaviFUS is conducting a FUS-mediated BBB opening combined with bevacizumab (Avastin) clinical trial at Linkou Chang Gung Memorial Hospital.
"If these two non-invasive FUS treatments for brain tumors can be successfully developed, they can offer non-invasive treatment options with improved efficacy and minimal side effects."

SynDevRx Announces Research Collaboration with Maine Medical Center Research Institute to Study the Effects of SDX-7320 In Obesity-Accelerated Multiple Myeloma Models

Retrieved on:

Tuesday, August 3, 2021

Branches of biology, Medical specialties, Medicine, Oncology, Multiple myeloma, Metástasis, Bone marrow, Cancer

The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma a form of cancer that develops in bone marrow.

Key Points:

The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma a form of cancer that develops in bone marrow.
"We're excited to test this drug, SDX-7320, in these models of cancers accelerated by obesity," lead investigator Michaela Reagan, PhD, said.
"Obesity changes the composition of the blood and bone marrow, making it more conducive for multiple myeloma cells to develop or proliferate.
"Maine Medical Center, and Dr. Reagan in particular, have some of the best models for illustrating the effects obesity has on the microenvironment of multiple myeloma," noted SynDevRx Sr. Director of Translational Research, Dr. Peter Cornelius, PhD.

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

Retrieved on:

Friday, July 23, 2021

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.

Key Points:

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.
The data further demonstrate that Castles DecisionDx-SCC test can provide clinicians with additional information on a patients metastatic risk to help them make more informed choices about their treatment and follow-up care.
All SCC tumor specimens were tested with DecisionDx-SCC and analyzed using Kaplan-Meier for metastasis-free survival (MFS) and Cox regression for risk of regional/distant metastasis.
DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.

United Breast Cancer Foundation Celebrates with Twisted Pink at 'An Evening Inspired' Gala

Retrieved on:

Tuesday, July 20, 2021

Cancer, Breast cancer, Medical specialties, Cancer pathology, Metástasis, Oncology, Metastatic breast cancer, The Breast

HUNTINGTON, N.Y., July 20, 2021 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) was proud to be the Title Patient Sponsor of Twisted Pink's 7th Annual Gala, "An Evening Inspired" , held on July 9th at Churchill Downs Millionaires Row, in Louisville, KY.

Key Points:

HUNTINGTON, N.Y., July 20, 2021 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) was proud to be the Title Patient Sponsor of Twisted Pink's 7th Annual Gala, "An Evening Inspired" , held on July 9th at Churchill Downs Millionaires Row, in Louisville, KY.
The Gala, with more than 400 in attendance, was an evening of hope, celebration and positivity, aiming to raise funds for metastatic breast cancer research.
Twisted Pink's mission of raising funds for metastatic breast cancer research benefits patients with breakthroughs.
"It was a wonderful evening filled with hope, compassion, the sharing of many stories regarding breast cancer journeys, and a vision for a better tomorrow for individuals affected by breast cancer."

Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET

Retrieved on:

Wednesday, July 7, 2021

Medical specialties, Oncology, Medicine, Health, Cancer, Delcath Systems, Interventional oncology, Metástasis

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference.

Key Points:

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference.
To learn more about the event or to schedule a one-on-one meeting with Delcaths management, please visit https://www.accesstogiving.com/ or email [email protected] .
Access to Giving is a first-of-its-kind virtual investor conference where companies will have the opportunity to present their story and conduct 1x1 meetings with qualified investors, for charity.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Retrieved on:

Wednesday, June 23, 2021

Cancer, Clinical medicine, Infectious causes of cancer, Carcinoma, Transitional cell carcinoma, Aging-associated diseases, Transitional epithelium, Bladder cancer, Kidney cancer, Metástasis, Avelumab, Checkpoint inhibitor

The objective of the ZiP-UP (Zirconium-girentuximab PET in Urothelial Cancer Patients) study is to evaluate the feasibility of using TLX250-CDx PET/CT1 in the detection of localised and metastatic urothelial carcinoma or bladder cancer.

Key Points:

The objective of the ZiP-UP (Zirconium-girentuximab PET in Urothelial Cancer Patients) study is to evaluate the feasibility of using TLX250-CDx PET/CT1 in the detection of localised and metastatic urothelial carcinoma or bladder cancer.
The trial will recruit 20 patients over 12 months: ten patients with known metastatic urothelial carcinoma or bladder cancer; and ten patients that require primary staging of localised urothelial carcinoma or bladder cancer.
Telix CEO, Dr Christian Behrenbruch added, We are pleased that a first patient has been dosed in this study exploring the clinical utility of TLX250-CDx to image other cancers, beyond renal cancer, and in indications where conventional imaging has limitations.
Bladder cancer is the sixth most commonly occurring cancer in men, and the tenth most common cancer overall worldwide.2 In 2020, 573,278 people worldwide were diagnosed with bladder cancer and 212,536 people died from their disease.3 Urothelial carcinoma (or UCC) accounts for ~90% of all bladder cancers.

Worldwide Malignant Ascites Industry to 2029 - by Key Treatment, Type of Application and Geography - ResearchAndMarkets.com

Retrieved on:

Tuesday, June 22, 2021

Health, Oncology, Oncology, Medical specialties, Medicine, Clinical medicine, Ovarian cancer, Malignancy, Ascites, Metástasis

Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global malignant ascites market.

Key Points:

Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global malignant ascites market.
Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global malignant ascites market.
This report concludes with company profiles section that highlights major information about the key players engaged in global malignant ascites market.
It is evident that malignant ascites play a key role in ovarian tumorigenesis, especially in the formation of metastases to peritoneal organs, and distant organs.

Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET

Retrieved on:

Monday, June 7, 2021

Medical specialties, Gastroenterology, Clinical medicine, Communication, Forward-looking statement, Necrobiosis, Cancer, Metástasis, Breast cancer, Colorectal cancer, Gastroparesis

The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.

Key Points:

The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.
Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).
The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties.
Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements.

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Retrieved on:

Tuesday, June 1, 2021

Tumor, Cancer pathology, Oncology, Tumor microenvironment, Metástasis, Branches of biology

This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.

Key Points:

This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.
TGF plays a key role in fibrosis and also promotes cancer growth and metastasis via its effects in the tumor microenvironment (TME).
The integrins v6 and v8 are expressed by cancer cells, and v6 is also expressed on epithelial cells in fibrotic diseases.
Corbus believes targeting both integrins at once is a rational approach to treating fibrotic diseases and carcinomas.

Golf Tournament for Young Woman Lost to Metastatic Breast Cancer

Retrieved on:

Friday, May 28, 2021

Cancer, Breast cancer, Metastatic breast cancer, Metástasis, Medical specialties, Health

ASSONET, Mass., May 27, 2021 /PRNewswire/ -- Play golf, fight cancer.

Key Points:

ASSONET, Mass., May 27, 2021 /PRNewswire/ -- Play golf, fight cancer.
On Friday, September 10, 2021, Piping Systems Inc. hosts its 4th Annual Tee for Cancer Free Golf Tournament atThe Fall River Country Club to honor Megan Lally, who sadly lost her battle to metastatic breast cancer on September 1, 2011.
The event is organized by Piping Systems, Inc., a well known piping contractor in Massachusetts, to benefit The Megan Lally Memorial Fund.
Pauline Lally, President of Piping Systems Inc., and Megan's mom helped form The Megan Lally Memorial Fund with Megan's friends and loved ones.Proceeds from the golf sponsorships fund the research for Metastatic Breast Cancer.